Navigation Links
Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
Date:1/13/2014

SEATTLE, Jan. 14, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio.

"We ended 2013 and have entered 2014 with a series of successes, including a global strategic partnership for pacritinib, positive reimbursement rulings in England/Wales and Germany for PIXUVRI, the reacquisition of rights to PIXUVRI and Opaxio in order to allow us to more efficiently move these programs forward and new positive interim data for tosedostat," said James A. Bianco, M.D. President and CEO of CTI. "We expect to continue that momentum with completion of the first of two Phase 3 clinical trials of pacritinib in myelofibrosis and potential topline data later in the year."

Progress Update

Pacritinib

  • In November 2013, CTI entered into a worldwide license agreement with Baxter International, Inc. (Baxter) to develop and commercialize pacritinib in which CTI and Baxter will jointly commercialize pacritinib in the United States and Baxter has exclusive commercialization rights for all indications outside the U.S.
  • The Phase 3 PERSIST-1 trial evaluating a broad set of myelofibrosis patients without limitations on blood platelet counts is currently enrolling patients. CTI expects to report topline data in the second half of 2014.
  • A second Phase 3 trial, PERSIST-2, in myelofibrosis patients with low platelet counts is expected to begin enrollment imminently. In October 2013, CTI reached agreement with the United States Food and Drug Administration (FDA) on a Special Protocol Assessment for this trial. This trial together with PERSIST-1 is intended to support registration in the U.S. and the Europea
    '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P. Morgan Healthcare Conference
2. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
3. ImmunoCellular Therapeutics Provides Update on 2014 Corporate Strategies and Milestones
4. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
5. Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds
6. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
7. PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
8. ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
9. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
10. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
11. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... Switzerland, Sept. 26, 2011 ... products manufacturers in the world, has launched an international ... of wilate® (von Willebrand Factor/Factor VIII Concentrate, ... pediatric and adult patients with Type 3 von Willebrand ...
... Vermillion, Inc. (NASDAQ: VRML ) a molecular ... Ph.D. as Chief Scientific Officer and Vice President Research ... of Vermillion,s two pipeline products, OVA2™ and VASCLIR®. Specifically, ... clinical studies for registration of these products. As part ...
Cached Medicine Technology:Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients 2Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients 3Vermillion Enhances Management Team With A Key Addition 2Vermillion Enhances Management Team With A Key Addition 3Vermillion Enhances Management Team With A Key Addition 4
(Date:7/13/2014)... Max International has recently ... be the featured guest at its Charity Exhibition and ... Attendees will learn about Max’s health products and ... basketball games and perform in a 3 point shoot-out. ... and energy-boosting supplements , has recently announced former NBA ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 According ... Vkool.com, this is a step by step guide on what ... impairment easily and quickly. Vkool writes in its review ... what foods to eat to revitalize their kidney health. Vkool ... book can help people reverse their damaged kidney functions naturally. ...
(Date:7/13/2014)... 2014 Celebrity fitness trainer and former ... promotional partnership with Aqua Health Labs for their flagship ... supplement . The collaboration was recently announced live on ... trainer , actor, model, and a two time World ... celebrities, he has prepared stars including Demi Moore, Hilary ...
(Date:7/13/2014)... Arbor, MI (PRWEB) July 13, 2014 If ... learning program he has just launched at http://www.HealthYourself101.com ... of visceral obesity. , Power has set out to ... its ill effects that’s actually – dare we say it? ... “The program,” says Power, “aims to engage the remote learner ...
Breaking Medicine News(10 mins):Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... in pediatric study , MONDAY, June 21 (HealthDay News) -- ... who later receive cochlear implants, a new study finds. , ... 3.2 years) who received ear tubes before cochlear implants. In ... removed before cochlear implantation surgery. In all the other cases, ...
... likely to develop allergies, asthma, study suggests , ... born vaginally pick up different bacteria than those who ... immune systems develop, a new study suggests. , ... born through cesarean sections appear to be more at ...
... of an ancient language provides new insights into the ... world. The study, "Dvandvas, Blocking, and the Associative: The ... in the June 2010 issue of the scholarly journal ... Stanford University. A preprint version is available on line ...
... environmental levels of the industrial chemical bisphenol A, or BPA, ... to testicular function, according to a new study conducted in ... Society,s 92nd Annual Meeting in San Diego. "We are ... to BPA levels that are lower than what the Food ...
... The recent revelation that the chair of the ... a tobacco executive until April 2010 sends an unfortunate ... longer a priority, states an editorial http://www.cmaj.ca/cgi/doi/10.1503/cmaj.100850 ... "There is simply no place for the tobacco industry ...
... ... behind the website. , ... June 21, 2010 -- The Active Search Results Search Engine ( www.activesearchresults.com ) announced today ... , , ,ASR Ranking allows search engines to rank search results higher for websites ...
Cached Medicine News:Health News:Ear Tubes Appear to Be Safe Before Cochlear Implantation 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 3Health News:The 'bumpy ride' of linguistic change 2Health News:Early-life exposure to BPA may affect testis function in adulthood 2Health News:CMAJ calls for resignation of IDRC chair Barbara McDougall 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 3
Anti Gliadin IgG Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... the semi-quantitative determination of specific IgA autoantibodies ... of the anti-Gliadin IgA assay can be ... of diseases associated with elevated levels of ... these autoantibodies are one indicator in a ...
... kit is used for the quantitative measurement ... plasma. This Free Estriol kit is a ... and controls are incubated with Estriol enzyme ... antibody. Free Estriol in the patients serum ...
... The Urisys 1800 System is the ... daily urinalysis workload in a convenient and ... is designed for optimized work and data ... sediment terminal.Fast processing of test strips accelerates ...
Medicine Products: